Omaha, NE – Streck, Inc., has added markers to CD-Chex CD117™ Plus, the first and only commercially
available positive procedural control for CD117, and now, CD25 and CD71.

CD-Chex CD117 Plus eliminates the need for laboratories to hold and validate patient samples to use as
a control for CD117, CD25 and CD71, saving time and money.

CD-Chex CD117 Plus was developed with characteristics similar to the abnormal peripheral blood
leukocytes often found in a hematolymphoid neoplastic patient sample. CD-Chex CD117 Plus possesses
surface CD117, CD25 and CD71 that are detectable with fluorescent monoclonal antibodies by flow
cytometry. Abnormal leukocytes are distinguishable from normal leukocytes on the basis of light scatter
properties and a low level of CD45 expression.

CD-Chex CD117 Plus features 30-day open-vial stability and 90-day closed-vial stability.

For Research Use Only. Not for use in diagnostic procedures.

Streck also offers CD-Chex Plus™, a positive procedural control for monitoring immunophenotyping by
flow cytometry. It provides the most assayed CD markers in the industry on a single control, including
those on the HIV panel of markers and a normal level of CD34+ cells. CD-Chex Plus is manufactured from
normal human peripheral blood leukocytes and erythrocytes and is available in two clinically relevant
levels of CD4+ cells.

About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The company’s pursuit of innovative solutions has produced an extensive list of patented products. Streck’s core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit

What we offer

Upcoming Events >